与TRP相关的基因特征预测直肠癌的生存率和免疫微环境:一项全面的生物信息学研究
Xiaojun Wang1, Jieqiong Peng2, Dong Song3
1Department of Gastroenterology and Hepatology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, China.
Frontiers in immunology
|September 18, 2025
概括
这项研究确定了五种与温度敏感受体 (TRP) 相关的生物标志物,用于直肠癌 (RC) 的预后. 这些发现为TRP在RC中的道作用和潜在的个性化治疗目标提供了新的见解.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学是一种遗传学.
背景情况:
- 结直肠癌 (RC) 的发病过程涉及复杂的生物机制.
- 在RC中温度敏感受体 (TRP) 通道的预后作用仍然在很大程度上未被描述.
- 了解TRP通道参与对于推进RC治疗策略至关重要.
研究的目的:
- 研究TRP相关基因在直肠癌 (RC) 的预后意义.
- 确定TRP通道在RC患者结局中的潜在临床影响.
- 探索TRP相关的生物标志物用于预测RC预后.
主要方法:
- 利用来自TCGA和GEO数据库的用于直肠癌 (RC) 患者的RNA-seq数据.
- 采用加权基因共同表达网络分析 (WGCNA) 和差异基因表达分析.
- 使用考克斯和LASSO回归确定了预后生物标志物,构建了一个名录和风险模型.
主要成果:
- 确定了与代谢途径相关的246个差异表达的TRP相关基因 (DETRPs).
- 开发了一个使用五个生物标志物 (BMP5,DHRS11,GLTP,NFE2L3,TMCC3) 与临床特征相关的预后模型.
- 揭示了高风险和低风险组之间的独特免疫细胞透模式,将特定生物标志物与免疫细胞类型联系起来.
结论:
- 确定了五种与TRP相关的新生物标志物,在直肠癌 (RC) 中具有显著的预后价值.
- 这些生物标志物提供了TRP通道功能在RC发展和进展的洞察力.
- 研究结果表明,TRP相关基因有可能成为个性化直肠癌治疗的治疗标.
相关概念视频
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...